The overall goal of the Penn/Wistar Skin Cancer Development Research Program (DRP) is to advance high quality research, foster new ideas, and to move research studies from pilot to project status. A second goal of the DRP is to create opportunities for the career development of junior faculty or senior investigators who are interested in transitioning into skin cancer research.
Specific aim 1 : To attract, select and fund the most outstanding proposals with significant potential to benefit the Skin Cancer SPORE and translational skin cancer research.
Specific aim 2 : To support and integrate the selected pilot projects into the SPORE program with established processes to review and monitor progress. Women and underrepresented minorities will be strongly encouraged to participate. The DRP has a transparent peer-reviewed selection process that incorporates defined criteria for funding decisions. We require that Developmental Research Awardees be active in SPORE functions, use the SPORE Core resource, and provide formal written progress reports. Within the context of the DRP, we have established high standards and expectations of the investigators and have established a formal process to review and monitor progress of funded pilots. The program measures success by resulting publications, resulting funding, stimulating new aims in existing SPORE projects, and elevation to new full projects for the future.

Public Health Relevance

The Development Research Program of the Penn/Wistar Skin Cancer SPORE will promote translational melanoma and skin cancer research by providing a mechanism for simulating grant applications for pilot projects. The applications go through committee review and with formal procedures for monitoring progress and ensuring integrations within the SPORE.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
1P50CA174523-01A1
Application #
8664627
Study Section
Special Emphasis Panel (ZCA1-RPRB-7 (J1))
Project Start
Project End
Budget Start
2014-09-15
Budget End
2015-03-31
Support Year
1
Fiscal Year
2014
Total Cost
$73,219
Indirect Cost
$33,641
Name
Wistar Institute
Department
Type
DUNS #
075524595
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Sarvi, Sana; Crispin, Richard; Lu, Yuting et al. (2018) ALDH1 Bio-activates Nifuroxazide to Eradicate ALDHHigh Melanoma-Initiating Cells. Cell Chem Biol 25:1456-1469.e6
Noguera-Ortega, Estela; Amaravadi, Ravi K (2018) Autophagy in the Tumor or in the Host: Which Plays a Greater Supportive Role? Cancer Discov 8:266-268
Jenkins, Russell W; Aref, Amir R; Lizotte, Patrick H et al. (2018) Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. Cancer Discov 8:196-215
Gangadhar, Tara C; Savitch, Samantha L; Yee, Stephanie S et al. (2018) Feasibility of monitoring advanced melanoma patients using cell-free DNA from plasma. Pigment Cell Melanoma Res 31:73-81
Zhang, Gao; Wu, Lawrence W; Mender, Ilgen et al. (2018) Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma. Clin Cancer Res 24:4771-4784
Natale, Christopher A; Li, Jinyang; Zhang, Junqian et al. (2018) Activation of G protein-coupled estrogen receptor signaling inhibits melanoma and improves response to immune checkpoint blockade. Elife 7:
Hu, Xiaowen; Sood, Anil K; Dang, Chi V et al. (2018) The role of long noncoding RNAs in cancer: the dark matter matters. Curr Opin Genet Dev 48:8-15
Liu, Shujing; Zhang, Gao; Guo, Jianping et al. (2018) Loss of Phd2 cooperates with BRAFV600E to drive melanomagenesis. Nat Commun 9:5426
Reyes-Uribe, Patricia; Adrianzen-Ruesta, Maria Paz; Deng, Zhong et al. (2018) Exploiting TERT dependency as a therapeutic strategy for NRAS-mutant melanoma. Oncogene 37:4058-4072
Yam, Clinton; Xu, Xiaowei; Davies, Michael A et al. (2018) A Multicenter Phase I Study Evaluating Dual PI3K and BRAF Inhibition with PX-866 and Vemurafenib in Patients with Advanced BRAF V600-Mutant Solid Tumors. Clin Cancer Res 24:22-32

Showing the most recent 10 out of 89 publications